ISIN | LU1540962054 |
---|---|
Valor Number | 35004489 |
Bloomberg Global ID | |
Fund Name | HBM Global Biotechnology Fund P USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 466.70 USD | 10.02.2025 |
---|---|---|
Previous Price * | 471.09 USD | 07.02.2025 |
52 Week High * | 522.40 USD | 08.11.2024 |
52 Week Low * | 426.07 USD | 19.04.2024 |
NAV * | 466.70 USD | 10.02.2025 |
Issue Price * | 466.70 USD | 10.02.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 20,399,074 | |
Unit/Share Assets *** | 16,373,839 | |
Trading Information SIX |
YTD Performance | +1.07% |
31.12.2024 - 10.02.2025
31.12.2024 10.02.2025 |
---|---|---|
YTD Performance (in CHF) | +1.44% |
31.12.2024 - 10.02.2025
31.12.2024 10.02.2025 |
1 month | +2.63% |
10.01.2025 - 10.02.2025
10.01.2025 10.02.2025 |
3 months | -10.34% |
11.11.2024 - 10.02.2025
11.11.2024 10.02.2025 |
6 months | -5.02% |
12.08.2024 - 10.02.2025
12.08.2024 10.02.2025 |
1 year | +1.36% |
12.02.2024 - 10.02.2025
12.02.2024 10.02.2025 |
2 years | +15.82% |
10.02.2023 - 10.02.2025
10.02.2023 10.02.2025 |
3 years | +17.52% |
16.02.2022 - 10.02.2025
16.02.2022 10.02.2025 |
5 years | +14.30% |
12.02.2020 - 10.02.2025
12.02.2020 10.02.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
argenx SE | 7.98% | |
---|---|---|
Gilead Sciences Inc | 4.75% | |
Vertex Pharmaceuticals Inc | 4.14% | |
Amgen Inc | 4.02% | |
Zealand Pharma AS | 3.83% | |
Regeneron Pharmaceuticals Inc | 3.66% | |
Alnylam Pharmaceuticals Inc | 3.63% | |
Insmed Inc | 3.55% | |
Ascendis Pharma AS ADR | 3.54% | |
Neurocrine Biosciences Inc | 3.51% | |
Last data update | 31.12.2024 |
TER | 0.0133% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.10% |
Ongoing Charges *** | 1.64% |
SRRI ***
|
|
SRRI date *** | 31.01.2025 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |